



Our STN: BL 125665/0

BLA APPROVAL
March 15, 2019

Siwa Biotech Corp.
Attention: William M. Canfield, MD, PhD
755 Research Parkway, Suite 125
Oklahoma City, OK 73104-3631

Dear Dr. Canfield:

Please refer to your Biologics License Application (BLA) submitted September 26, 2017, received September 28, 2017, under section 351(a) of the Public Health Service Act (PHS Act) for Blood Grouping Reagent, Anti-Fy^b (Murine Monoclonal) (Recombinant).

LICENSING

We are issuing Department of Health and Human Services U.S. License No. 2080 to Siwa Biotech Corp., Oklahoma City, Oklahoma, under the provisions of section 351(a) of the PHS Act controlling the manufacture and sale of biological products. The license authorizes you to introduce or deliver for introduction into interstate commerce, those products for which your company has demonstrated compliance with establishment and product standards.

MANUFACTURING LOCATIONS

Under this license, you are approved to manufacture Blood Grouping Reagent, Anti-Fy^b (Murine Monoclonal) (Recombinant) at your facility located at Oklahoma City, Oklahoma. The final product will be filled at the following facility location:

(b) (4)

You may label your product with the proprietary name SIWA Anti-Fy^b and market it as approved in your license application.

ADVISORY COMMITTEE

We did not refer your application to the Blood Products Advisory Committee because our review of information submitted in your BLA, including the clinical study design and trial results, did not raise concerns or controversial issues that would have benefited from an advisory committee discussion.

DATING PERIOD

The dating period for Blood Grouping Reagent, Anti-Fy^b (Murine Monoclonal) (Recombinant) shall be 24 months from the date of manufacture when stored at 2-8 °C. The date of manufacture shall be defined as the date of the (b) (4) .

FDA LOT RELEASE

You are not currently required to submit samples or protocols of future lots of Blood Grouping Reagent, Anti-Fy^b (Murine Monoclonal) (Recombinant) to the Center for Biologics Evaluation and Research (CBER) for release by the Director, CBER, under 21 CFR 610.2(a). We will continue to monitor compliance with 21 CFR 610.1 requiring completion of tests for conformity with standards applicable to each product prior to release of each lot.

BIOLOGICAL PRODUCT DEVIATIONS

You must submit reports of biological product deviations under 21 CFR 600.14. You should identify and investigate all manufacturing deviations promptly, including those associated with processing, testing, packaging, labeling, storage, holding and distribution. If the deviation involves a distributed product, may affect the safety, purity, or potency of the product, and meets the other criteria in the regulation, you must submit a report on Form FDA 3486 to the Director, Office of Compliance and Biologics Quality, at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71-G112
Silver Spring, MD 20993-0002

MANUFACTURING CHANGES

You must submit information to your BLA for our review and written approval under 21 CFR 601.12 for any changes in, including but not limited to, the manufacturing, testing, packaging or labeling of the Blood Grouping Reagent, Anti-Fy^b (Murine Monoclonal) (Recombinant), or in the manufacturing facilities.

LABELING

We hereby approve the draft package insert labeling submitted under amendment 17, dated November 21, 2018. This is a reminder that as of September 24, 2014, medical devices that are licensed under the PHS Act are subject to certain provisions of the final Unique Device Identifier (UDI) rule. These provisions include the requirement to provide a UDI on the device label and packages (21 CFR 801.20), format dates on the device label in accordance with 21 CFR 801.18, and submit data to the Global Unique

Device Identification Database (GUDID) (21 CFR 830 Subpart E). Additionally, please identify each device identifier implemented for the subject device, and the device identifiers that have been discontinued for the subject device as a labeling change in an annual report consistent with 21 CFR 601.12(f)(3). For more information on these requirements, please see the UDI website at <http://www.fda.gov/udi>.

Please submit all final printed labeling as a PDF electronic copy (eCopy) at the time of use and include implementation information on Form FDA 356h as appropriate.

Two draft copies of the proposed introductory advertising or promotional labeling may be voluntarily submitted for advisory comment with a completed Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71-G112
Silver Spring, MD 20993-0002

ADVERSE EVENT REPORTING

You must submit adverse experience reports in accordance with the Medical Device Reporting (MDR) requirements for medical devices (21 CFR 803) as required by 21 CFR 600.80(k)(2). Because your product is characterized as a device as well as a biologic, submit these reports to the MedWatch System using MedWatch Reporting Form 3500A or an electronic equivalent. Please refer to the *Questions and Answers about eMDR – Electronic Medical Device Reporting – Guidance for Industry, User Facilities and FDA Staff* at <https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm175805.htm>.

Required reports are to be submitted to:

Food and Drug Administration
Center for Devices and Radiological Health
MDR Policy Branch
10903 New Hampshire Avenue
WO Bldg. 66, Room 3217
Silver Spring, MD 20993-0002

Sincerely,

Mary A. Malarkey
Director
Office of Compliance and Biologics Quality
Center for Biologics
Evaluation and Research

Nicole Verdun, MD
Director
Office of Blood Research and Review
Center for Biologics
Evaluation and Research